Skip to main content
Clinical Trials/NCT02408302
NCT02408302
Unknown
Phase 4

Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children: A Prospective Randomized Control Study

Carmel Medical Center1 site in 1 country90 target enrollmentApril 2015

Overview

Phase
Phase 4
Intervention
Midazolam
Conditions
Dormicum
Sponsor
Carmel Medical Center
Enrollment
90
Locations
1
Primary Endpoint
time until sedation is achieved
Last Updated
11 years ago

Overview

Brief Summary

Currently Midazolam sedation is the standard of care for minor invasive procedures in pediatric patients; its use is restricted to two routes of administration for this purpose oral and intranasal.

A third route of administration (buccal) is tested and approved for seizure management. In the investigators' study the researchers investigate the buccal route of administration versus oral or intranasal administration for sedation. The investigators' hypothesis is that buccal route of administration is more convenient than intranasal and better absorbed than oral.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
March 2016
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Carmel Medical Center
Responsible Party
Principal Investigator
Principal Investigator

Muriel Konopnicki

Head of Pediatric emergency room

Carmel Medical Center

Eligibility Criteria

Inclusion Criteria

  • age 5 months to 6 years.
  • need to undergo a minimal invasive procedure that requires light sedation.
  • ASA (American Society of Anesthesiologists) I-II
  • parent that can read, understand and sign an informed consent form

Exclusion Criteria

  • patients with life threatening conditions.
  • patients with respiratory or cardiac chronic illnesses or ASA other than I-II.
  • patients with traumatic injury for the nose or the oral cavity.
  • patients that would not or cannot take the drug in the route picked in a randomized way.

Arms & Interventions

oral midazolam

oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.

Intervention: Midazolam

intranasal midazolam

intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure

Intervention: Midazolam

buccal midazolam

buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure

Intervention: Midazolam

Outcomes

Primary Outcomes

time until sedation is achieved

Time Frame: 1 hour

duration of sedation

Time Frame: 4 hour

time from achieving sedation until reaching full consciousness

convenience of administration

Time Frame: 15 minutes

described by the parent and the physician by a numerical rating scale (NRS) questionaire

efficacy of the sedation

Time Frame: 4 hours

described by the parent, nurse and physician by a NRS questionaire

Study Sites (1)

Loading locations...

Similar Trials